New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 3, 2014
07:41 EDTBIIBBiogen price target raised to $340-$350 from $300-$304 at Wells Fargo
Wells Fargo increased its price target on Biogen as the firm began including revenue from the company's Spinal Muscular Atrophy treatment in its model. Wells keeps a Sector Perform rating on the stock.
News For BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
April 27, 2015
10:07 EDTBIIBForward Pharma receives decision to grant from EPO for DMF patent in Europe
Forward Pharma (FWP) announced that the company received a decision to grant from the European Patent Office regarding its patent application 14172398.1 which covers, among other things, the treatment of multiple sclerosis with 480 mg per day of dimethyl fumarate wherein the pH controlled release compositions have an enteric coat. The EPO projects that the application will issue under the patent number EP2801355 on May 20, 2015 with the publication of the mention of grant. We expect that the patent will provide protection until October 2025, assuming the company successfully defends the patent during any subsequent invalidation proceedings. This projected European patent is one of several elements of the company's intellectual property, which also includes three U.S. pending patent applications and two other European pending patent applications covering methods of treating multiple sclerosis with formulations that provide a 480 mg daily dose of DMF. Foward Pharma said "The EPO examiner allowed our 480 mg patent claims after considering third party observations both requesting the EPO to not grant the application as well as suspend its examination. Biogen (BIIB) markets Tecfidera, a product containing DMF as the active ingredient for the treatment of MS at a daily dose of 480 mg. Tecfidera was approved by the European Commission in January 2014. Worldwide sales of Tecfidera as reported by Biogen totalled over $3.2B in the last 12 months, including $614M of ex-US sales."
09:19 EDTBIIBBiogen shares should be bought on weakness, says BMO Capital
Subscribe for More Information
08:25 EDTBIIBBiogen coverage assumed with a Perform at Oppenheimer
Subscribe for More Information
08:15 EDTBIIBBiogen weakness creates buying opportunity, says RBC Capital
Subscribe for More Information
April 24, 2015
15:16 EDTBIIBBiogen sell off a buying opportunity, Barron's says
Biogen is down about 6% on the session after reporting Q1 results that missed expectations. The pullback represents a buying opportunity as the company's drug pipeline should fuel strong growth, Barron's says. Reference Link
09:28 EDTBIIBPiper says Biogen has 'long way to go' before being top pick again
Subscribe for More Information
09:20 EDTBIIBOn The Fly: Pre-market Movers
UP AFTER EARNINGS: eHealth (EHTH), up 24.7%... Starbucks (SBUX), up 4.2%... Microsoft (MSFT), up 5.2%... Google (GOOG, GOOGL), up 3.2% and up 3.7%, respectively... Amazon (AMZN), up 12% after reporting quarterly results and announcing shopping app for Apple Watch... Gigamon (GIMO), up 16.5%... Juniper Networks (JNPR), up 6.6%. ALSO HIGHER: Molycorp (MCP), up 10.2% following a Bloomberg report that China's export tax decision may boost rare earth demand... Mattel (MAT), up 4.4% after being upgraded to Buy from Neutral at Goldman... Innocoll (INNL), up 13.1% after 3.3M share Secondary priced at $9.00... Cytosorbents (CTSO), up 9.7% after CEO comments on CytoSorb in letter to shareholders. DOWN AFTER EARNINGS: Biogen (BIIB), down 4.7%... Altera (ALTR), down 1.7%... Pandora (P), down 4%... ResMed (RMD), down 8.7%... Xerox (XRX), down 4.7%... HomeAway (AWAY), down 3.6% after reporting quarterly results and departure of officers. ALSO LOWER: Ubiquiti (UBNT), down 14.4% following CFO resignation and preliminary third quarter results... 3D Systems (DDD), down 10.4% after reporting preliminary first quarter results... StemCells (STEM), down 23.2% after filing to sell common stock... Aerie Pharmaceuticals (AERI), down 54.7% after Rhopressa Phase 3 trial did not meet primary endpoint.
07:40 EDTBIIBForward Pharma price target raised to $53 from $43 at Leerink
Subscribe for More Information
07:02 EDTBIIBBiogen reports Q1 Tecfidera revenue $825M
Total multiple sclerosis product sales were $2.1 billion compared to $1.7 billion in the same quarter last year. Interferon revenues, including Avonex and Plegridy were $755M in Q1. Tysabri revenues were $463M. Net revenues relating to Rituxan and Gazyva were $331M. Elocate revenues were $54M, Alprolix revenues were $43M.
07:01 EDTBIIBBiogen reports Q1 adjusted EPS $3.82, consensus $3.91
Subscribe for More Information
April 23, 2015
15:07 EDTBIIBBiogen technical comments before earnings
Subscribe for More Information
15:01 EDTBIIBNotable companies reporting before tomorrow's open
Subscribe for More Information
April 21, 2015
08:52 EDTBIIBBiogen April weekly volatility elevated into Q1 and outlook
Biogen April weekly call option implied volatility is at 74, May is at 35, June is at 32, July is at 31; compared to its 26-week average of 33 according to Track Data, suggesting large near term price movement into the expected release of Q1 results on April 24.
07:31 EDTBIIBBiogen says data presented from ATTAIN study demonstrate efficacy of Plegridy
Subscribe for More Information
April 20, 2015
07:32 EDTBIIBBiogen says new data supports Tecfidera as long-term treatment for MS patients
Subscribe for More Information
07:18 EDTBIIBAmerican Academy of Neurology to hold annual meeting
Subscribe for More Information
April 15, 2015
07:14 EDTBIIBBiogen volatility flat into new drug data
Biogen overall option implied volatility of 35 compares to its 26-week average of 34 according to Track Data, suggesting non-directional into results as shares rally in the preopen on Phase 2 RENEW study of anti-LINGO-1 in acute optic neuritis clinical data.
April 14, 2015
18:30 EDTBIIBOn The Fly: After Hours Movers
Subscribe for More Information
16:12 EDTBIIBBiogen presents new Anti-LINGO-1 Phase 2 AON data
Subscribe for More Information
11:25 EDTBIIBPTAB declares interference between Forward Pharma and Biogen regarding treatment
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use